-
Implementation of Medicines Pricing Policies in Sub-Saharan Africa: Protocol for a Systematic Review
A new systematic review analyzing drug pricing policies in sub-Saharan Africa. -
Perspectives on the Cost Effectiveness Threshold in Health Care for the United States
Webinar 5Comments
-
FDA-Authorized COVID-19 Vaccines are Effective Per Real-World Evidence Synthesized Across a Multi-State Health System
This study demonstrates the real-world effectiveness of COVID-19 vaccines.Comments
-
Therapeutic Proteins and Oral Vaccines Market to Surpass $300,000 Mn by 2027 Opens in a new window)
The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.Comments
-
Protecting the Most Vulnerable by Vaccinating the Most Active
In this Perspective, researchers use a network simulation model to illustrate five different vaccination strategies for coronavirus disease 2019 (COVID-19).Comments
-
Operation Warp Speed
Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing ChallengesComments
-
ICER Releases Draft Evidence Report on Therapies for Multiple Myeloma
Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple MyelomaComments
-
Potential Savings from Accelerating US Approval of Complex Generics
A subset of generic prescription drugs, complex generics are copies of non-biologic medicines that have a complex molecular base, route of delivery, formulation, or dosage form.Comments
-
US Drug Prices Rise Over 4% in 2021 Reversing Multi-Year Trend of Slowed Growth Opens in a new window)
Usually in January, every year, a large number of pharmaceutical companies update product prices - a trend that often receives public attention in the media, for better or for worse.Comments
-
The Health Costs of Cost-Sharing
Cost-sharing schemes should be evaluated based on their overall impact on welfare, which can be very different from the price elasticity of demand.Comments
-
Market Access of orphan Designated Therapies at Risk Due to Payer Assessment of Value Opens in a new window)
Current drug assessments place an unfair burden on rare disease drugs in comparison to non-rare disease drugs.Comments
-
CBO’s Model of Drug Price Negotiations Under the Elijah E. Cummings Lower Drug Costs Now Act: Working Paper 2021-01
This working paper describes CBO's simulation model of drug price negotiations under the Elijah E. Cummings Lower Drug Costs Now Act in detail, including its data sources and parameter values, and the sensitivity of the results.Comments
-
Price Increases Continue to Outpace Inflation for Many Medicare Part D Drugs
Half of all Part D-covered drugs (50%, or 1,646 drugs) had list price increases that exceeded the rate of inflation between July 2018 and July 2019.Comments
-
The Most Successful Oncology Drug Portfolios of the Past Decade
Supplementary information.Comments
-
A Global Pharmaceutical Launch Count
Which nation is the most attractive destination for prescription drug launches?Comments
Comments